Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI) from its SEC filings: 2025 revenue $0, free cash flow -$422.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $0 |
| Net income | -$512.5 million |
| Free cash flow | -$422.1 million |
| Diluted EPS | $-2.97 |
| Cash | $201.5 million |
| Share count, 1 year | +9% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.